

Re: RENORMAX®
Docket No. 95E-0076

JUL 10 1995

The Honorable Bruce Lehman
Assistant Secretary of Commerce and
Commissioner of Patents and Trademarks
Washington, D.C. 20231

Dear Commissioner Lehman:

This is in regard to the application for patent term extension for U.S. Patent No. 4,470,972, filed by Schering Corporation, under 35 U.S.C. § 156 et seq. We have reviewed the dates contained in the application and have determined the regulatory review period for RENORMAX®, the human drug product claimed by the patent.

The total length of the regulatory review period for RENORMAX® is 3,996 days. Of this time, 2,901 days occurred during the testing phase and 1,095 days occurred during the approval phase. These periods of time were derived from the following dates:

1. The date an exemption under subsection 505(i) of the Federal Food, Drug, and Cosmetic Act involving this drug product became effective: January 22, 1984.

FDA has verified the applicant's claim that the date the Investigational New Drug application (IND) became effective was on January 22, 1984.

2. The date the application was initially submitted with respect to the human drug product under subsection 505(b) of the Federal Food, Drug, and Cosmetic Act: December 31, 1991.

FDA has verified the applicant's claim that the New Drug Application (NDA) for RENORMAX® (20-240) was initially submitted on December 31, 1991.

3. The date the application was approved: December 29, 1994.

FDA has verified the applicant's claim that NDA 20-240 was approved on December 29, 1994.

OFFICE OF THE ASSISTANT
COMMISSIONER FOR PATENTSRECEIVED
JUL 12 1984

RENORMAX® - Page 2

This determination of the regulatory review period by FDA does not take into account the effective date of the patent, nor does it exclude one-half of the testing phase as required by 35 U.S.C. § 156(c)(2).

Please let me know if we can be of further assistance.

Sincerely yours,

A handwritten signature in black ink, appearing to read 'Stuart L. Nightingale', with a long horizontal flourish extending to the right.

Stuart L. Nightingale, M.D.
Associate Commissioner
for Health Affairs

cc: Thomas D. Hoffman
Schering-Plough Corporation
Patent Department (K-6-1-1990)
2000 Galloping Hill Road
Kenilworth, NJ 07033-0530